Novo Nordisk says competition in semaglutide will be driven by science and quality, not pricing, as multiple generic versions prepare to enter India after patent expiry
Source :- Companies Read More
Novo Nordisk says competition in semaglutide will be driven by science and quality, not pricing, as multiple generic versions prepare to enter India after patent expiry